VEXIM Secures a Contingent Equity Line PACEO® with SOCIETE GENERALE

  VEXIM Secures a Contingent Equity Line PACEO® with SOCIETE GENERALE

Business Wire

TOULOUSE, France -- October 30, 2013

Regulatory News :

Vexim S. A. (Paris:ALVXM) (FR0011072602 - ALVXM), a medical device company
specialized in minimally-invasive solutions for the treatment of vertebral
fractures, announces that it has negotiated a contingent equity line with
SOCIETE GENERALE, exercisable by tranches at VEXIM’s discretion, as authorized
by the Shareholders’ Meeting of June 18, 2013.

This optional equity financing will allow VEXIM, to broaden its financial
flexibility in order to continue its strong commercial development, while
diversifying its financial tools and minimizing dilution for its shareholders.

At VEXIM’s request, SOCIETE GENERALE is committed to subscribe to successive
capital increases over the next 24 months, within the global limit of 450,000
shares, being 9.8% of the 4,590,645 shares currently outstanding.

Should the entire contingent equity line be drawn down by the emission of
450000 new shares, a shareholder who currently owns 1% of the company’s share
capital would see his or her share ownership reduced to 0.91%.

For each emission of shares, the issue price will depend on the average market
share price discounted by no more than 8%. This discount will enable SOCIETE
GENERALE, as a financial intermediary with no intention of remaining
shareholder in the company, to underwrite the subscription, regardless of
capital market volatility.

VEXIM has no minimum drawdown obligation, and only intends to use this
facility if market conditions allow financing that it is in the best interest
of both the Company and its shareholders.


                             Next press release:

                       *2013 annual sales: January 2014
  *2013 annual results: March 2014

About Vexim, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), Vexim is a medical device company
created in February 2006. The Company has specialized in the creation and
marketing of mini-invasive solutions for treating traumatic spinal
pathologies. Benefitting from the financial support of its longstanding
shareholders, Truffle Capital^1 and Banexi Venture, and from OSEO public
subsidies, Vexim has designed and developed the SpineJack®, a unique implant
capable of repairing a fractured vertebra and restoring the balance of the
spinal column. The Company currently has 50 staff. It has its own sales teams
in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well
as distributors notably in Turkey, Argentina, India, Taiwan and in the
following countries where the product is currently being registered: Mexico,
Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. Vexim has been listed on
NYSE Alternext Paris since May 3^rd 2012.
For further information, please go to

SpineJack®^2, a revolutionary implant for treating Vertebral Compression
The revolutionary aspect of the SpineJack® lies in its ability to restore a
fractured vertebra to its original shape, restore the spinal column’s optimal
anatomy and thus remove pain and enable the patient to recover their
functional capabilities. Thanks to a specialized range of instruments,
inserting the implants into the vertebra is carried out by mini-invasive
surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to
be discharged shortly after surgery. The SpineJack® range consists of 3
titanium implants with 3 different diameters, thus covering 95% of vertebral
compression fractures and all patient morphologies.
SpineJack® technology benefits from the support of international scientific
experts in the field of spine surgery and worldwide patent protection until

  *Name: VEXIM
  *ISIN code: FR0011072602
  *Ticker: ALVXM

^1 Founded in 2001 in Paris, Truffle Capital is a leading independent European
private equity firm. It is dedicated to investing in and building technology
leaders in the IT, life sciences and energy sectors. Truffle Capital manages
€550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked
during 7 to 10 years). For further information, please visit

^2 This medical device is a regulated health product that, with regard to
these regulations, bears the CE mark. Please refer to the Instructions for


Vincent Gardès, Tel: +33 5 61 48 48 38
Financial Communications and Investor Relations
Dusan Oresansky / Emmanuel Huynh
Tel: +33 1 44 71 94 92
Alize RP
Press Relations
Caroline Carmagnol, Tel: +33 6 64 18 99 59
Christian Berg, Tel: +33 1 70 22 53 86
Press spacebar to pause and continue. Press esc to stop.